Related Experiment Video
Updated: Mar 1, 2026
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
Published on: August 31, 2022
Molecular characterization of the A52 murine hepatocellular carcinoma cell line
Rhys Gillman1,2,3, Eun Jin Sun1, Miriam Wankell1
1Department of Biomedical Sciences and Molecular and Cell Biology, College of Medicine and Dentistry, College of Science and Engineering, James Cook University, Townsville, Queensland, Australia.
Background:
To combat hepatocellular carcinoma (HCC) disease heterogeneity and growing mortality, there is an urgent need for targeted and personalized therapeutics. While syngeneic mouse models are commonly used for preclinical validation of these therapeutics, the lack of genetically characterized murine cell lines adds uncertainty to the study of drug-gene interactions in these models. We previously generated a novel murine cell line, A52, from a diethylnitrosamine (DEN)-induced adiponectin-knockout mouse model. Here, we present a comprehensive genomic and transcriptomic characterization of the A52 cell line.
Methods:
A52 cells were grown in various culture medium compositions to investigate robustness to simple media. Whole-genome sequencing (WGS) and RNAseq were performed on A52 cells from both cell culture and syngeneic tumor tissue, as well as a reference cell line representing non-tumor cells, AML-12.
Results:
A52 was found to show robust growth in all medium compositions. Substantial chromosomal instability was observed in A52, including trisomy 15 and notable amplifications of oncogenic loci such as Myc and Cd274 (PDL-1), alongside frequent small variants and structural rearrangements. Notably, the cell line harbors the common HCC driver Braf V584E mutation, and a novel Plk1 p.R364W variant predicted as a driver mutation. Transcriptomic profiling defined a distinct "A52 gene signature" enriched in EGFR-ERBB signaling and cell migration pathways. Integrative analyses demonstrated that the A52 gene signature aligns closely with a subset of human HCC lacking CTNNB1 mutations.
Conclusion:
This study provides a critical genetic resource, facilitating more precise preclinical modeling and therapeutic validation in HCC.
Insights
This study characterizes the A52 murine cell line, revealing significant genomic instability and key mutations relevant to hepatocellular carcinoma (HCC) drug development. The findings provide a valuable resource for preclinical HCC research.
Area of Science:
- Genomics and Transcriptomics
- Cancer Biology
- Preclinical Therapeutics
Background:
- Hepatocellular carcinoma (HCC) presents significant mortality and heterogeneity, necessitating personalized therapies.
- Syngeneic mouse models are crucial for preclinical drug validation but require genetically characterized cell lines.
- The A52 murine cell line was previously generated from a diethylnitrosamine-induced adiponectin-knockout model.
Purpose of the Study:
- To provide a comprehensive genomic and transcriptomic characterization of the A52 murine cell line.
- To assess the utility of the A52 cell line for preclinical modeling of hepatocellular carcinoma.
- To identify genetic features that can inform targeted therapeutic strategies for HCC.
Main Methods:
- Whole-genome sequencing (WGS) and RNA sequencing (RNAseq) were performed on A52 cells and AML-12 (a reference cell line).
- A52 cells were cultured in various media to assess growth robustness.
- Genomic and transcriptomic data were analyzed to identify mutations, chromosomal abnormalities, and gene expression signatures.
Main Results:
- A52 cells exhibit robust growth and significant chromosomal instability, including trisomy 15 and amplifications of oncogenes Myc and Cd274 (PDL-1).
- The cell line harbors the common HCC driver Braf V584E mutation and a novel Plk1 p.R364W variant.
- Transcriptomic profiling revealed an "A52 gene signature" enriched in EGFR-ERBB signaling and cell migration pathways, aligning with a subset of human HCC.
Conclusions:
- The comprehensive characterization of the A52 cell line offers a valuable genetic resource for HCC research.
- This resource will facilitate more precise preclinical modeling and therapeutic validation for hepatocellular carcinoma.
- The identified genetic features and gene signature can guide the development of targeted therapies for specific HCC subtypes.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
05:06A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
Published on: October 24, 2015